Mansuy · Tobacco control 2026 · Regulatory framework and mechanistic review · n=?

Identifying substances suspected of facilitating inhalation or increasing nicotine uptake as part of the enforcement of the Tobacco Products Directive.

Cited 1 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Mechanism-based reasoning and regulatory policy framework without primary human experimental data.

PubMed 40473412 · doi:10.1136/tc-2024-059111 · record verified 2026-08-29

What was done

The authors developed a mechanistic framework to define and classify substances that facilitate inhalation or enhance nicotine uptake under the European Union Tobacco Products Directive (TPD 2014/40/EU). The framework focuses on three specific mechanisms: increasing nicotine bioavailability, decreasing nicotine-related irritation or aversion, and increasing nicotine concentration in aerosols. Based on available literature, the authors compiled a list of substances meeting these criteria to guide regulatory enforcement.

What was found

The abstract reports no numerical or quantitative experimental values. The authors identified specific substance classes with inhalation-facilitating properties, including TRPM8 receptor agonists and β2-adrenoreceptor agonists. They recommended a complete ban on the listed substances in combustible tobacco products (cigarettes, roll-your-own tobacco, cigars, cigarillos, pipe tobacco, and waterpipe tobacco). For electronic cigarette liquids, they recommended banning most listed additives while conducting a specific risk-benefit analysis for menthol and other TRPM8 receptor agonists due to their common use by smokers attempting cessation.

Why it matters

This framework operationalizes ambiguous regulatory wording in tobacco directives, providing regulators with concrete mechanistic criteria and candidate substance lists to restrict additives designed to make nicotine products easier or harsher to inhale.

Limits

The abstract describes no primary empirical data collection, human pharmacokinetic trials, or formal systematic review methodology. The substance classifications rely primarily on mechanistic plausibility rather than direct comparative uptake measurements across standard delivery devices.

Cited by